Metagenomi Therapeutics, Inc. Research and Development Expense
Metagenomi Therapeutics, Inc. (MGX) reported Research and Development Expense of $22.51 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-10
- Metagenomi Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $22.51M, a 0.02% increase year-over-year.
- Metagenomi Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $19.30M, a 23.24% decline year-over-year.
- Metagenomi Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $21.50M, a 7.18% decline year-over-year.
- Metagenomi Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $25.28M, a 3.71% decline year-over-year.
- Metagenomi Therapeutics, Inc. research and development expense for fiscal 2025 was $94.43M, a 13.51% decline from fiscal 2024.
- Metagenomi Therapeutics, Inc. research and development expense for fiscal 2024 was $109.18M, a 15.65% increase from fiscal 2023.
- Metagenomi Therapeutics, Inc. research and development expense for fiscal 2023 was $94.40M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $22.51M 10-Q · filed 2026-08-10 | $41.81M 10-Q · filed 2026-08-10 | $63.31M derived: sum of 3 quarters · filed 2026-08-10 | $88.60M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $19.30M 10-Q · filed 2026-05-11 | $40.80M derived: sum of 2 quarters · filed 2026-05-11 | $66.08M derived: sum of 3 quarters · filed 2026-05-11 | $88.59M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $21.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $46.78M derived: sum of 2 quarters · filed 2026-03-05 | $69.29M derived: sum of 3 quarters · filed 2026-08-10 | $94.43M 10-K · filed 2026-03-05 |
| 2025-09-30 | $25.28M 10-Q · filed 2025-11-12 | $47.79M derived: sum of 2 quarters · filed 2026-08-10 | $72.93M 10-Q · filed 2025-11-12 | $96.10M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $22.51M 10-Q · filed 2026-08-10 | $47.65M 10-Q · filed 2026-08-10 | $70.81M derived: sum of 3 quarters · filed 2026-08-10 | $97.07M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $25.14M 10-Q · filed 2026-05-11 | $48.31M derived: sum of 2 quarters · filed 2026-05-11 | $74.56M derived: sum of 3 quarters · filed 2026-05-11 | $102.88M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $23.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $49.42M derived: sum of 2 quarters · filed 2026-03-05 | $77.74M derived: sum of 3 quarters · filed 2026-03-05 | $109.18M 10-K · filed 2026-03-05 |
| 2024-09-30 | $26.26M 10-Q · filed 2025-11-12 | $54.58M derived: sum of 2 quarters · filed 2025-11-12 | $86.02M 10-Q · filed 2025-11-12 | $110.77M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $28.32M 10-Q · filed 2025-08-12 | $59.76M 10-Q · filed 2025-08-12 | $84.51M derived: sum of 3 quarters · filed 2025-08-12 | $111.35M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $31.44M 10-Q · filed 2025-05-13 | $56.19M derived: sum of 2 quarters · filed 2025-05-13 | $83.03M derived: sum of 3 quarters · filed 2025-05-13 | $105.71M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $24.75M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $51.59M derived: sum of 2 quarters · filed 2025-03-17 | $74.27M derived: sum of 3 quarters · filed 2025-03-17 | $94.40M 10-K · filed 2025-03-17 |
| 2023-09-30 | $26.84M 10-Q · filed 2024-11-13 | $49.52M derived: sum of 2 quarters · filed 2024-11-13 | $69.65M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $22.68M 10-Q · filed 2024-08-14 | $42.81M 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $20.13M 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |